Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From KAI Pharmaceuticals
Finance Watch: Another VC Mega-Round As Flare Raises $123m Series B
Private Company Edition: Flare Therapeutics, targeting transcription factors to discover precision medicines, had big pharma backing for its second venture capital financing. Also, Mediar closed a $10m series A round, Switch launched with $52m and EpiBiologics raised a $50m series A round.
No Slowdown From Bayer On Business Development Front
“We're looking at opportunities almost on a weekly basis,” Bayer’s pharma chief Stefan Oelrich told Scrip as the German major posted a solid set of financials for the fourth quarter.
Dealmaking Quarterly Statistics, Q4 2022
During Q4, biopharma merger and acquisition value reached $35.7bn and drew in $62.1bn in potential deal value from alliances. Device company M&A values reached $19.2bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $4.8bn.
Five Challenges Bill Anderson Faces At Bayer
Six weeks after leaving Roche, Bill Anderson is taking the helm at Bayer in one of the most intriguing appointments in the sector for some time.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.